"A Study to Evaluate Drug-drug Interactions and Safety Between BR3006-1, BR3006-2, and BR3006-3 in Healthy Volunteers"

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 22, 2023

Primary Completion Date

September 11, 2023

Study Completion Date

September 11, 2023

Conditions
Diabetes Mellitus
Interventions
DRUG

BR3006-1

All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.

DRUG

BR3006-2

All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.

DRUG

BR3006-3

All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.

Trial Locations (1)

Unknown

CHA Bundang Medical Center(CBMC), Seongnam-si

All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY